3,800
+1.60%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kaken Pharmaceutical Co
Its shares trade on Tokyo Stock Exchange under the ticker 4521.T. It has been listed since 2 October 1961. In the fiscal year to 31 March 2026, it reported revenue of ¥76.87bn and net income of ¥2.14bn. At that date it held total assets of ¥178.22bn and shareholders' equity of ¥147.62bn.
Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. The company is headquartered in Bunkyo-Ku, Tokyo-To. The firm operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Oct 1961
- Employees
- 1,268
- Website
- kaken.co.jp ↗
Leadership
Pay as last reported
- Mr. Hiroyuki HoriuchiPresident, Representative Director, since 2016
- Mr. Masashi SuzudoManaging Director, since 2021
- Mr. Tomoyuki KosekiExecutive Officer, Chief Director of Sales
- Mr. Tatsuhiro HaradaExecutive Officer, Deputy Chief Director of Research and Development, Manager of New Drug Discovery Center
- Mr. Keizo KimuraExecutive Officer, Manger of Production, Manager of Shizuoka Plant
- Mr. Masaru OgawaExecutive Officer, Manager of Regulatory Affairs
- Mr. Mitsuru WatanukiChief Director of Research Development, Director, since 2022
- Mr. Masahiro MatsuuraDirector, since 2018
- Mr. Yasuhiro UmedaDirector
- Mr. Yasutomo InoueIndependent Director
- Ms. Satoko IshikawaIndependent Director
- Mr. Shoichiro TakagiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong product portfolio, including a wide range of pharmaceutical and healthcare products.
- Established brand reputation and recognition in the pharmaceutical industry.
- Robust research and development capabilities, driving innovation and product development.
- Extensive distribution network, ensuring widespread availability of products.
Weaknesses
- Limited global presence, with most operations concentrated in Japan.
- Dependence on a few key products, putting the company at risk if these products face challenges.
- Relatively small size compared to larger pharmaceutical companies, limiting resources and market reach.
- Vulnerability to regulatory changes and compliance requirements, impacting operations.
Opportunities
- Growing demand for pharmaceutical products, particularly in emerging markets.
- Expansion into international markets to diversify revenue streams and reduce reliance on the Japanese market.
- Increasing focus on research and development partnerships for accelerated product development.
- Potential adoption of digital and technological advancements to enhance operations and reach.
Threats
- Intense competition from larger pharmaceutical companies with greater resources.
- Stringent regulatory requirements and approval processes for new drugs and healthcare products.
- Economic fluctuations and uncertainty affecting consumer spending on healthcare products.
- Potential disruptions in the supply chain and manufacturing processes due to unforeseen events.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.